Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.07 USD
Change Today -0.003 / -4.29%
Volume 14.0K
VGLS On Other Exchanges
Symbol
Exchange
OTC US
As of 9:39 AM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

vg life sciences inc (VGLS) Snapshot

Open
$0.07
Previous Close
$0.07
Day High
$0.07
Day Low
$0.07
52 Week High
05/1/14 - $0.25
52 Week Low
12/15/14 - $0.04
Market Cap
2.8M
Average Volume 10 Days
84.6K
EPS TTM
$-18.00
Shares Outstanding
41.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VG LIFE SCIENCES INC (VGLS)

Related News

No related news articles were found.

vg life sciences inc (VGLS) Related Businessweek News

No Related Businessweek News Found

vg life sciences inc (VGLS) Details

VG Life Sciences, Inc., a development stage biotechnology company, engages in the research and development of therapeutic and diagnostic pharmaceutical and medical products. The company focuses on the development of drugs and disease treatments using two platform technologies, Targeted Peptide Technology (TPT) and Metabolic Disruption Technology (MDT). It has three drug research programs in, at, or near clinical stage including a TPT therapy for HIV/AIDS; a TPT therapy for Lyme disease; and an MDT therapy for treatment-refractory, or drug-resistant, cancer starting with ovarian cancer. The company also researches TPT programs that are in various preclinical stages for traumatic brain injury, hypertension, preeclampsia, glioblastoma, type I and type II diabetes, Crohn’s disease, rheumatoid arthritis, ulcerative colitis, lymphedema, staphylococcus, streptococcus, sepsis infection, multiple sclerosis, transplant rejection, and pediatric autoimmune neuropsychiatric disorders. It is also involved in the development of oils, including diesel and other transportation fuels, as well as edible, cosmetic, and nutraceutical oils. The company was formerly known as Viral Genetics, Inc. and changed its name to VG Life Sciences, Inc. in November 2012. VG Life Sciences, Inc. was founded in 1995 and is based in San Marino, California.

3 Employees
Last Reported Date: 02/11/15
Founded in 1995

vg life sciences inc (VGLS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: --
Co-Founder, Chairman, Vice President of Resea...
Total Annual Compensation: $292.5K
Chief Financial Officer and Director
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

vg life sciences inc (VGLS) Key Developments

VG Life Sciences Inc. Progress Update Phase I Cancer Study

VG Life Sciences announced an update to its physician-initiated IND phase I study to test safety and tolerability of its patented technology in patients with advanced stage solid tumors. Primary investigator and medical oncologist Dr. Tyler Curiel, MD, MPH reported, "the trial has completed enrollment of the final cohort (cohort #4) using the maximum doses of sorafenib (800 mg) combined with hydroxychloroquine (400 mg). There are sufficient evaluable patients to conclude that this combination, maximum dose and schedule are sufficiently safe for additional clinical testing." The study, which is ongoing in patients with refractory or relapsed solid tumors, examines the safety and efficacy of hydroxychloroquine (HCQ), in combination with sorafenib (marketed as Nexavar), which was co-developed by Bayer AG and Onyx Pharmaceuticals. Noteworthy in terms of tolerance, two patients in this final cohort are still receiving treatment at maximum drug doses and are in cycle 6, which is encouraging. They will continue with additional cycles until the patients fail according to protocol. A third patient was withdrawn from the study for unrelated infection. Based on current results, the safety and tolerability of this drug combination at these maximum doses have been established to allow for planned expansion studies in the most promising cancers studied to date with this combination. Based on clinical leads seen thus far, additional testing in patients with sarcomas, non-small cell lung cancer, epithelial ovarian cancer and triple negative breast cancer are being considered.

VG Life Sciences Inc. Reports Clinical Outcomes in Phase I Cancer Study

VG Life Sciences announced an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors. The study reported two clinical responses in cohort 3 with disease stabilization in a patient with metastatic ovarian cancer for 4 months, and disease stabilization going into its fifth month in a patient with triple negative breast cancer. The final patient in cohort #3 has stage IV (metastatic) adenocarcinoma of the lung. The four separate lung lesions have all regressed about 20%. The study, which is ongoing in patients with refractory or relapsed solid tumors, examines the safety and efficacy of hydroxychloroquine (HCQ), in combination with sorafenib (marketed as Nexavar(R)), which was co-developed by Bayer AG and Onyx Pharmaceuticals.

VG Life Sciences, Inc. Announces Update on Phase I Cancer Study

VG Life Sciences Inc. announced an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors. This study is being conducted at the Cancer Therapy and Research Center at the University of Texas Health Sciences Center at San Antonio. The primary investigator is medical oncologist Tyler Curiel, M.D., MPH and is based on the research of Dr. M. Karen Newell-Rogers, PhD VG Life Sciences Inc.'s Chief Scientific Advisor. The study, which is ongoing in patients with refractory or relapsed solid tumors, examines the safety and efficacy of hydroxychloroquine (HCQ), in combination with sorafenib (marketed as Nexavar(R)), which was co-developed by Bayer AG and Onyx Pharmaceuticals. VG Life Sciences Inc. holds the use patent for this combination treatment. The study is reporting two clinical responses in cohort 3: disease stabilization in a patient with metastatic ovarian cancer for 4 months, and disease stabilization going into its fifth month in a patient with triple negative breast cancer. Further test information and data will be forthcoming. The fourth and final cohort will begin in January which will increase the HCQ dosage from cohort 3. For procedural reasons the start of the final cohort was delayed as previously reported.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VGLS:US $0.07 USD -0.003

VGLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VGLS.
View Industry Companies
 

Industry Analysis

VGLS

Industry Average

Valuation VGLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VG LIFE SCIENCES INC, please visit www.viralgenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.